Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence

This article was originally published in The Gray Sheet

Executive Summary

diaDexus and GlaxoSmithKline are in the early stages of developing a joint diagnostic and therapeutic approach to treat patients by detecting and inhibiting an enzyme that may predict instances of cardiovascular disease

You may also be interested in...



diaDexus PLAC test for heart disease

Adjunctive, predictive laboratory test for congestive heart disease receives 510(k) clearance July 18. The blood test measures the level of the enzyme lipoprotein-associated phospholipase A2, which is created by macrophages when a person has CHD, FDA explains. "An elevated PLAC test result with an LDL-cholesterol level of less than 130 mg/dL gives doctors increased confidence that patients have two-to-three times the risk of having [CHD] when compared with patients having lower PLAC test results," according to the agency. The test was developed by San Francisco-based diaDexus and GlaxoSmithKline (1"The Gray Sheet" June 10, 2002, p. 8)...

diaDexus PLAC test for heart disease

Adjunctive, predictive laboratory test for congestive heart disease receives 510(k) clearance July 18. The blood test measures the level of the enzyme lipoprotein-associated phospholipase A2, which is created by macrophages when a person has CHD, FDA explains. "An elevated PLAC test result with an LDL-cholesterol level of less than 130 mg/dL gives doctors increased confidence that patients have two-to-three times the risk of having [CHD] when compared with patients having lower PLAC test results," according to the agency. The test was developed by San Francisco-based diaDexus and GlaxoSmithKline (1"The Gray Sheet" June 10, 2002, p. 8)...

Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs

Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel